Support for fast pharmaceutical regulatory approval

Our intelligence on approved and pipeline drugs, plus regulatory information on devices/diagnostics help you plan your route to commercial success.

To achieve commercial success, you need to connect successful approved drugs and mid-to-late stage pipeline drugs to the underlying trial information. You’ll also want to focus in on the best trial designs and comparator arms that have met with success across target markets.

What we offer

Our solutions give you the tools and intelligence to quickly build up a landscape of approved and pipeline drugs for a disease of interest. We cover where drugs have been approved or are in development, and timeline projections for clinical trials and time to regulatory approvals.
You’ll also be able to find comprehensive, accurate regulatory information on devices/diagnostics, particularly for FDA and CE Mark approvals.
Plus, you can save time filtering information by mechanism of action or drug class.

How it helps

We’ll help you:

Stay up to date with new regulatory trends/changes in pharma and medtech
Anticipate label claims of your competitors and ensure your product has a strong and promising future in the market
Learn from the pitfalls of terminated trials for similar drugs
Understand successful (and unsuccessful) strategies to achieve priority regulatory designations, that you can incorporate into your own development plans
Tap into the industry’s top analysts to help with your research needs

Generics Bulletin

Chirag Patel And Chintu Patel Return As Co-CEOs Of Amneal

By David Wallace 25 Oct 2022

Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.

Pink Sheet

What Breast Cancer Drug Developers Need to Know Now About Regulatory Policies

21 Oct 2022

As biopharma continues to make progress developing novel and more targeted cancer therapies, regulators are responding with innovative and collaborative approaches to reviewing cancer products, aiming to resolve questions earlier and review products more quickly. Pink Sheet closely covers these programs, helping readers understand the expectations, challenges and opportunities, as well as lessons from companies putting policy into practice. This ebook takes some of our recent articles on special review mechanisms and regulators’ data expectations.

Biomedtracker

Biomedtracker 2018 Early Outlook Report

28 Jul 2022

What's on the horizon for pharma in 2018? Find out with Biomedtracker's Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.

Pink Sheet

Trumps Drug Pricing Plan: The Headlines Are The Goal - But Also A Threat

By Michael McCaughan 16 Jun 2022

The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.

Pink Sheet

China-US Relationship Hinges On Changing Internal, External Forces

By Brian Yang 16 Jun 2022

Given the ongoing election challenges in the US, China has yet to officially congratulate Joe Biden as the next US president, although many world leaders are already hailing a reset in US foreign policy. Many are wondering if this and other moves indicate a quiet internal shift for China's high tech and life sciences sectors, just days after Beijing concluded a high-level plenary meeting outlining its priorities for the next five years.

Biomedtracker, Meddevicetracker

Q2 2022 Outlook Report

23 May 2022

In this report, we cover catalysts from 31 drugs, devices, diagnostics, and deals expected to occur in the second quarter of 2022.

Biomedtracker, Meddevicetracker

Don’t miss your free extract of Early 2022 Outlook Report

08 Feb 2022

In pharma’s fast paced and continually evolving world, accurately anticipating the impact of events on the horizon is critical to your success.

Pink Sheet

Accelerated Approval Makes Big Splash In 2021 Novel Agents, Despite Crackdown On ‘Dangling’ Cancer Claims

By Bridget Silverman 19 Jan 2022

US FDA’s accelerated approvals hit a contemporary high in 2021, accounting for one-third of novel US approvals, but the big story was the agency’s crackdown on delinquent confirmatory trials for oncology AA indications.

Generics Bulletin

Medicines For Ireland Appoints New Chairs Following Framework Agreement

By Chloe Kent 18 Jan 2022

Medicines for Ireland has appointed Accord Healthcare Ireland managing director Padraic O’Brien as chairperson and Teva Ireland director of generic products Paul Neill as vice chairperson of the Irish industry association. The changes come just a few weeks after Ireland implemented its new framework agreement on off-patent pricing.

Pink Sheet

Care Needed With Plain Language Summaries Of EU Study Results

By Vibha Sharma 18 Jan 2022

The EU will make it mandatory for clinical trial sponsors to prepare layperson summaries of their study results. Industry practices around content presentation, translation and dissemination of these documents will be keenly watched.

Generics Bulletin

Multiple Molecules See UK Prices More Than Double In December

By David Wallace 18 Jan 2022

WaveData’s compilation of the fastest-rising UK generics prices in December showed several products across multiple presentations more than doubling their average trade prices to independent pharmacists.

HBW Insight

US FDA Says White Paper Could Inform Rulemaking For Cosmetic Talc-Asbestos Testing

By Ryan Nelson 14 Jan 2022

Formed by the FDA in fall 2018 and convened in early 2020 for a public meeting, the Interagency Working Group on Asbestos in Consumer Products maintains that electron microscopy should be a first-line method for detecting asbestos in cosmetic talc and talc-containing products, and that labs should report elongate mineral particles beyond those classically understood as asbestos.

Pink Sheet

Download your free accelerated trials article pack for insights into the latest developments

07 Dec 2021

Don’t miss updates on recent news in accelerated trials and its implications for drug development in the United States.

Generics Bulletin

Bio-Thera’s Bevacizumab US Action Date Passes Without Approval

By David Wallace 01 Dec 2021

GB2112_27_November_2021_Calendar_2GY47JX_1200

Bio-Thera Solutions had been hoping to become the first Chinese biosimilars developer to win an FDA approval, for its BAT1706 bevacizumab candidate. However, the announced FDA action date for the application has come and gone with no word from the company or regulator.

Pink Sheet

Divided US FDA AdComm Backs Molnupiravir Authorization But Wants More Studies

By Brenda Sandburg 01 Dec 2021

In 13-10 vote, panel finds reduction in COVID-19 hospitalizations and deaths outweighs risks. Four members say FDA should reconsider authorization if a more effective and safer therapy comes along. They concur molnupiravir should not be recommended for use in pregnancy but available to those who want it.

Support for fast pharmaceutical regulatory approval

Your window on the pipeline

Relevant products

Below are the Product List

Biomedtracker: see the drug development process through analysts’ eyes

HBW Insight: Health, Beauty and Wellness

Pink Sheet: global policy and regulatory coverage

Pharma Intelligence latest insights

Latest headlines

Next steps

This is Contactus Section

Request a live demo

Speak to Sales

Client Services

Pharma Report Store